At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 255 enrolled
Drug / intervention
Sodium oligo-mannurarate 600mg +2 moredrug
Likely dose
Sodium oligo-mannurarate 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease
Shanghai Greenvalley Pharmaceutical Co., Ltd.·interventional·Posted Oct 18, 2011·Updated Jan 27, 2015
In Brief
A Phase 2 clinical trial evaluating Sodium oligo-mannurarate 600mg, Sodium oligo-mannurarate 900mg, and 1 other intervention for Alzheimer Disease and Cognitive Impairment. Completed, enrolled 255 participants across 24 sites.
Detailed Summary
The primary purpose of this study is to determine whether sodium oligo-mannurarate capsule is effective and safe in the treatment of mild to moderate alzheimer' disease, and to determine the best therapeutic dose of sodium oligo-mannurarate capsule.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Cognitive Impairment
CountriesChina
CollaboratorsShanghai Mental Health Center
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedOct 2011
Primary CompletionAug 2013
TodayJul 2026
First PostedOct 18, 2011
Enrollment StartOct 1, 2011
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.7 years ago
Interventions
Sodium oligo-mannurarate 600mgdrug
sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
Sodium oligo-mannurarate 900mgdrug
sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
Placebodrug
simulant of sodium oligo-mannurarate capsule